Literature DB >> 8352659

Resistance of mice vaccinated with rabies virus internal structural proteins to lethal infection.

Y Takita-Sonoda1, H Fujii, K Mifune, Y Ito, M Hiraga, A Nishizono, K Mannen, N Minamoto.   

Abstract

Mice were vaccinated with recombinant vaccinia virus (rVac) expressing the glycoprotein (G), nucleoprotein (N), phosphoprotein (NS) or matrix protein (M) of rabies virus and their resistance to peripheral lethal infection with street rabies virus was examined. Mice vaccinated with rVac-G or rVac-N developed strong antibody responses to the corresponding proteins and essentially all mice survived challenge infection. Mice vaccinated with rVac-NS or rVac-M developed only a slight antibody response, however, a significant protection (59%) was observed in the rVac-NS-vaccinated mice, whereas rVac-M-vaccinated mice were not protected. No anti-G antibodies were detected in the sera of mice which has been vaccinated with rVac-N or rVac-NS and survived challenge infection. Passive transfer of anti-N monoclonal antibodies (MAbs) recognizing an epitope located on amino acids 1-224 of the protein prior to challenge resulted in significant protection, although the protection was not complete even with a high amount of antibodies. In contrast, none of the mice given MAbs recognizing an epitope of amino acids 247-415 or F(ab')2 fragments from a protective MAb IgG were protected. Administration of anti-CD 8 MAb to rVac-N-vaccinated mice showed no significant effect on protection. Our observations suggest that a considerable part of the protection achieved by the vaccination with rVac-N can be ascribed to the intact anti-N antibodies recognizing an epitope located on amino acids 1-224 of the protein.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8352659     DOI: 10.1007/bf01309843

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  36 in total

1.  Passive protection studies in mice with monoclonal antibodies directed against the non-structural protein NS3 of dengue 1 virus.

Authors:  C H Tan; E H Yap; M Singh; V Deubel; Y C Chan
Journal:  J Gen Virol       Date:  1990-03       Impact factor: 3.891

2.  Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-sepharose.

Authors:  P L Ey; S J Prowse; C R Jenkin
Journal:  Immunochemistry       Date:  1978-07

3.  Use of a vaccinia-rabies recombinant virus for the oral vaccination of foxes against rabies.

Authors:  B Brochier; I Thomas; B Bauduin; T Leveau; P P Pastoret; B Languet; G Chappuis; P Desmettre; J Blancou; M Artois
Journal:  Vaccine       Date:  1990-04       Impact factor: 3.641

4.  Induction of protective immunity against rabies by immunization with rabies virus ribonucleoprotein.

Authors:  B Dietzschold; H H Wang; C E Rupprecht; E Celis; M Tollis; H Ertl; E Heber-Katz; H Koprowski
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

5.  Amplification of rabies virus-induced stimulation of human T-cell lines and clones by antigen-specific antibodies.

Authors:  E Celis; T J Wiktor; B Dietzschold; H Koprowski
Journal:  J Virol       Date:  1985-11       Impact factor: 5.103

6.  Interleukin 2 increases protection against experimental rabies.

Authors:  P Perrin; M L Joffret; C Leclerc; D Oth; P Sureau; L Thibodeau
Journal:  Immunobiology       Date:  1988-05       Impact factor: 3.144

7.  A recombinant human adenovirus vaccine against rabies.

Authors:  L Prevec; J B Campbell; B S Christie; L Belbeck; F L Graham
Journal:  J Infect Dis       Date:  1990-01       Impact factor: 5.226

8.  A mouse model of the pathogenesis and postexposure prophylaxis of rabies.

Authors:  K Mifune; A Shichijo; Y Makino; E Takeuchi; A Yamada; K Sakamoto
Journal:  Microbiol Immunol       Date:  1980       Impact factor: 1.955

9.  Vaccinia virus recombinants expressing rabiesvirus glycoprotein protect against rabies.

Authors:  J Esposito; K Brechling; G Baer; B Moss
Journal:  Virus Genes       Date:  1987-11       Impact factor: 2.332

10.  Laboratory techniques in rabies: vaccine for man prepared in human diploid cells.

Authors:  H Koprowski
Journal:  Monogr Ser World Health Organ       Date:  1973
View more
  5 in total

1.  Highly attenuated poxviruses induce functional priming of neutrophils in vitro.

Authors:  R Förster; G Wolf; A Mayr
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

2.  Immunogenicity and relative attenuation of different vaccinia-rabies virus recombinants.

Authors:  J H Zhu; J Wang; B Cai; W Zhao; Y Zhu; R Chao; L Chen; H Xue; B L Ying; C P Li; Q L Hu; J Sha; J J Esposito
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

3.  Expression of the nucleoprotein of rabies virus in Escherichia coli and mapping of antigenic sites.

Authors:  H Goto; N Minamoto; H Ito; T R Luo; M Sugiyama; T Kinjo; A Kawai
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

4.  Efficacy of Favipiravir (T-705) in Rabies Postexposure Prophylaxis.

Authors:  Kentaro Yamada; Kazuko Noguchi; Takashi Komeno; Yousuke Furuta; Akira Nishizono
Journal:  J Infect Dis       Date:  2015-12-09       Impact factor: 5.226

5.  A simple and rapid immunochromatographic test kit for rabies diagnosis.

Authors:  Akira Nishizono; Pakamatz Khawplod; Kamruddin Ahmed; Kazuyo Goto; Seiji Shiota; Kumato Mifune; Takehito Yasui; Katsuyoshi Takayama; Yukuharu Kobayashi; Kazuaki Mannen; Veera Tepsumethanon; Chanarong Mitmoonpitak; Satoshi Inoue; Kinjiro Morimoto
Journal:  Microbiol Immunol       Date:  2008-04       Impact factor: 1.955

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.